ELYSIUM
THERAPEUTICS

November 3, 2023

Dear Investor:

We are pleased to provide you with an update on our progress in our programs as well as the financing round that we initiated last fall.

O2P™ Program – hPOC Study

We have now dosed 61 healthy volunteers with ETR028 and/or ETR029 up to a four-pill equivalent dose. From a safety perspective, the onsite principal investigator has described our drugs as "benign," which may be the most positive descriptor for safety of a new drug. The blended one- and two-pill doses demonstrated a unique pharmacokinetic (PK) profile, showing known analgesic levels of hydrocodone that could allow for once-a-day dosing. While the four-pill cohort has been dosed, we are awaiting the safety and PK data. At four pills, we expect to begin seeing evidence of the oral overdose protection feature with less than dose-proportional increase in the maximum hydrocodone exposure. If this study is successful, O2P hydrocodone would be the first demonstration of oral overdose protection for an acute-use opioid in humans. We could achieve this milestone by year-end if dosing for the remaining cohorts goes according to plan. Positive data would position O2P hydrocodone for potential Breakthrough Therapy Designation, an FDA process that would expedite its development and approval, as well as a potential commercial licensing deal.

XpiRx™ ("Expiring Pill") Program

As previously reported, we consider the XpiRx program a backup program subject to the results of the O2P hPOC study; thus, we are not currently investing in this program.

SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) Program

Fentanyl, a highly potent synthetic opioid, was responsible for nearly 70% of drug overdose deaths in 2022, killing over a quarter of a million Americans since 2018. Fentanyl's high potency and long duration of action frequently requires multiple doses of naloxone (like Narcan®) to effectively reverse a fentanyl overdose and restore breathing, because it wears off well before fentanyl has been eliminated from the body. Moreover, the discomfort of withdrawal symptoms and short-lived reversal attending Narcan enables many individuals to reuse immediately upon discharge from medical care, increasing the risk of death from a repeat overdose. While Indivior recently obtained approval for its nalmefene intranasal delivery device, OPVEE™, data does not support the longer duration of action needed to combat synthetic opioid (e.g., fentanyl) overdose – especially when taken orally.

Unlike short-acting Narcan, which may require six to 10 doses to safely transport a synthetic opioid overdose victim to the hospital, a single dose of SOOPR is designed not only to rapidly rescue an individual from a fentanyl overdose but will continue to effectively block opioid receptors for 12-24 hours. This reduces risk of re-narcotization, or the return of overdose symptoms, and thus, significantly reduces the likelihood of death or serious brain injury. SOOPR's long duration of action will also (i) prevent same-day re-use of opioids potentially leading to another overdose, and (ii) provide loved ones of individuals suffering from opioid use disorders and first responders with the peace of mind that comes from knowing they are equipped to save a life and help someone on the road to recovery. Importantly, SOOPR will also

provide unmatched protection to the substantial population of individuals who are unable, or refuse, to be admitted to emergency rooms.

We are pleased that we have already demonstrated in vivo proof of concept in animal models for a superior duration of action vs. Narcan™ and Opvee™. With funds from the recent financing, we have:

- Identified a potential delivery device partner that has an existing autoinjector that has been previously approved by the FDA for emergency use and appears capable of delivering SOOPR at targeted doses;
- Completed additional in vivo studies to demonstrate SOOPR's rapid onset and longer duration of action; and,
- Begun to prepare a pre-IND package for the FDA, which will enable agreement upon the development path for SOOPR based on the recent (May 2023) approval of Opvee.

With the above data, and agreement with the FDA on the development path for SOOPR, we plan to pursue a potential commercial licensing deal in 2024 to accelerate development of this much needed, life-saving product.

Financing

We are grateful to all our investors and granting agencies (i.e., NIH and Ohio Third Frontier) for funding our mission to disrupt the prescription opioid market by developing a new generation opioid pain relievers with unprecedented safety, and an opioid overdose rescue agent designed specifically to combat the devastating rise in fatalities from highly potent synthetic opioids. We expect to raise additional funds in 2024 to advance our programs toward commercialization. Additional funding could be from one or a combination of equity financing, non-dilutive grant funding or licensing deals.

We have the opportunity save thousands of lives and generate significant value, and we are emboldened by the results thus far in the O2P clinical study and additional SOOPR in vivo data.

If you have questions, please feel free to contact me.

Thank you and best regards,



A. Greg Sturmer
President and CEO
(650) 464-6175
gsturmer@elysiumrx.com